Description
LY-2603618 is an inhibitor of checkpoint kinase (CHK) 1 that exhibits anticancer chemotherapeutic activity. In various animal models with tumor xenografts, this compound inhibits the S phase DNA damage checkpoint and increases DNA damage. In lung cancer cells, LY-2603618 induces G2/M phase cell cycle arrest and autophagy. LY-2603618 also enhances activity of other co-administered chemotherapeutics such as gemcitabine.